Traditionally, monoanalyte biomarkers (e.g., chromogranin, serotonin, pancreastatin, etc.)were the primary carcinoid biomarkers in the management of carcinoid tumors, but the clinical utility of monoanalytes is currently obstructed by several inherent limitations, discussed below. The gene discussed is CHGA; the disease is carcinoid tumor.